BR112018003877A2 - “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica” - Google Patents

“composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”

Info

Publication number
BR112018003877A2
BR112018003877A2 BR112018003877-6A BR112018003877A BR112018003877A2 BR 112018003877 A2 BR112018003877 A2 BR 112018003877A2 BR 112018003877 A BR112018003877 A BR 112018003877A BR 112018003877 A2 BR112018003877 A2 BR 112018003877A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
reducing
body weight
subcutaneous fat
drug
Prior art date
Application number
BR112018003877-6A
Other languages
English (en)
Inventor
Ling Yu-Fang
Original Assignee
Caliway Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58186932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018003877(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2015/088340 external-priority patent/WO2016029870A1/zh
Application filed by Caliway Biopharmaceuticals Co., Ltd. filed Critical Caliway Biopharmaceuticals Co., Ltd.
Publication of BR112018003877A2 publication Critical patent/BR112018003877A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Abstract

a presente invenção fornece uma composição farmacêutica para reduzir gordura localizada, que compreende micelas contendo droga, feitas de tensoativos, e curcumina encapsulada nas ditas micelas contendo droga. esta composição farmacêutica para redução de gordura localizada pode reduzir a gordura no local de administração, e tem as vantagens de alta estabilidade, alta biodisponibilidade no tecido adiposo, poucos efeitos colaterais e liberação sustentada.
BR112018003877-6A 2015-08-28 2016-08-26 “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica” BR112018003877A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/088340 2015-08-28
PCT/CN2015/088340 WO2016029870A1 (zh) 2014-08-28 2015-08-28 用于减少局部脂肪与减少体重的组合物及其医药品与应用
US201562257846P 2015-11-20 2015-11-20
US62/257,846 2015-11-20
US201662299702P 2016-02-25 2016-02-25
US62/299,702 2016-02-25
PCT/IB2016/055102 WO2017037594A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途

Publications (1)

Publication Number Publication Date
BR112018003877A2 true BR112018003877A2 (pt) 2018-09-25

Family

ID=58186932

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018003892-0A BR112018003892A2 (pt) 2015-08-28 2016-08-26 ?composição farmacêutica e método para a redução da gordura?
BR112018003877-6A BR112018003877A2 (pt) 2015-08-28 2016-08-26 “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018003892-0A BR112018003892A2 (pt) 2015-08-28 2016-08-26 ?composição farmacêutica e método para a redução da gordura?

Country Status (15)

Country Link
US (4) US20180243211A1 (pt)
EP (2) EP3381473A4 (pt)
JP (5) JP7063804B2 (pt)
KR (4) KR102240221B1 (pt)
CN (3) CN108697668B (pt)
AU (5) AU2016314546C1 (pt)
BR (2) BR112018003892A2 (pt)
CA (2) CA2995158C (pt)
CO (1) CO2018003424A2 (pt)
IL (1) IL257784B2 (pt)
MX (3) MX2018002462A (pt)
RU (1) RU2753507C2 (pt)
SG (1) SG11201801111RA (pt)
TW (3) TWI604859B (pt)
WO (2) WO2017037594A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537548B2 (en) 2014-08-28 2020-01-21 Caliway Biopharmaceuticals Co., Ltd. Composition and medical product for reducing body weight and body fat, and use of said product
AU2016314546C1 (en) * 2015-08-28 2021-07-22 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
CA3033041A1 (en) 2016-08-26 2018-03-01 Caliway Biopharmaceuticals Co., Ltd. A subcutaneous injection formulation for reducing body weight and uses thereof
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
TWI676476B (zh) * 2017-03-28 2019-11-11 康霈生技股份有限公司 用於減少體重及減少體脂肪的組合物及其醫藥品與應用
EP3946407A4 (en) * 2019-03-24 2022-12-28 Patel, Naishadhkumar Ramubhai FORMULATION TO INCREASE THE BIOAVAILABILITY AND STABILITY OF CURCUMINOIDS AND/OR THEIR DERIVATIVES THEREOF
CN110934827B (zh) * 2019-11-08 2021-03-19 江西中医药大学 一种口服葛根素混合胶束制剂、制备方法及应用
CN113730650B (zh) * 2021-10-13 2022-11-01 哈尔滨泽润医疗机构管理有限公司 一种碳水溶酶组合物及其制备方法和应用
WO2023192259A1 (en) * 2022-03-28 2023-10-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity
US20230372378A1 (en) * 2022-05-16 2023-11-23 Caliway Biopharmaceuticals Co., Ltd. Compositions and methods for alleviating conditions caused by abnormal subcutaneous deposit of adipose tissue or fat

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
EP1156782B1 (en) * 1999-03-03 2005-05-04 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
ATE346059T1 (de) * 1999-08-16 2006-12-15 Dsm Ip Assets Bv Verfahren zu herstellung von epigallocatechin gallate
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US20040071799A1 (en) 2001-02-12 2004-04-15 Xiurong Xu Herbal compositions and methods for effecting weight loss in humans
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
DE602004022806D1 (de) 2003-06-04 2009-10-08 Nestec Sa Getränk zur gewichtskontrolle
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050232974A1 (en) * 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
US20060188590A1 (en) 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
AU2006210114B2 (en) * 2005-02-04 2011-11-17 Peter Heger Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
ITFI20050031A1 (it) 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
JP2007063137A (ja) 2005-08-29 2007-03-15 Daicho Kikaku:Kk 抗肥満薬
WO2007041276A2 (en) 2005-09-29 2007-04-12 New Chapter, Inc. Methods for modulating apoptosis, cellgrowth, and protein expression with herbal compositions
JP2007131603A (ja) 2005-11-14 2007-05-31 Kaneka Corp Ｌ−カルニチン合成系酵素遺伝子の転写促進用組成物
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
US9192644B2 (en) * 2006-03-06 2015-11-24 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders
EA200802090A1 (ru) 2006-03-31 2010-04-30 ДСМ АйПи АССЕТС Б.В. Новое применение соединений и комбинаций соединений для улучшения внешнего вида
US7977319B1 (en) 2006-04-03 2011-07-12 Scott David Levine Ultra-high fiber supplement and method of reducing weight, cardiovascular risks and ingested toxins
WO2007113008A2 (en) * 2006-04-04 2007-10-11 Dsm Ip Assets B.V. Opaque container comprising food or pharmaceutical products or herbal(s)
CN101095665A (zh) * 2006-06-27 2008-01-02 中国科学院上海生命科学研究院 Sirt1在预防、控制或治疗肥胖中的用途
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
CN101310718A (zh) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 减肥降血脂的含儿茶素的组合物及其用途
CN102357226B (zh) 2007-08-07 2013-07-10 北京北大维信生物科技有限公司 中草药姜黄的醇提取物在制备具有脂肪酶活性抑制作用的药物中的应用
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
EP2249806A2 (en) * 2008-01-08 2010-11-17 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
KR101372658B1 (ko) * 2008-06-25 2014-03-14 이엘씨 매니지먼트 엘엘씨 피부 및 신체 외관 개선 방법 및 조성물
AU2009307753A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
US8496974B2 (en) * 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent
CA2748344A1 (en) 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
ES2604127T3 (es) * 2009-03-20 2017-03-03 Bioxtract S.A. Composición farmacéutica que presenta propiedades antiinflamatorias
CN101874763A (zh) * 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN101632655B (zh) 2009-08-04 2011-12-07 南京大渊美容保健有限公司 延缓衰老的白藜芦醇和生物类黄酮营养组合物
JP5594819B2 (ja) 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
PE20130198A1 (es) * 2010-03-10 2013-03-24 Abbvie Bahamas Ltd Composiciones solidas
US8835509B2 (en) * 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
US20130245118A1 (en) * 2010-07-02 2013-09-19 Eric H. Kuhrts Stable fatty acid-containing formulations
WO2012003176A1 (en) 2010-07-02 2012-01-05 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
KR101640258B1 (ko) * 2010-07-05 2016-07-15 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
US20130143869A1 (en) 2010-07-16 2013-06-06 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
US20120088829A1 (en) * 2010-09-29 2012-04-12 MyCell Holdings Limited Formulations of Ubiquinol and Resveratrol Esters
CN102106816A (zh) 2010-12-16 2011-06-29 天津迈迪瑞康生物医药科技有限公司 一种白藜芦醇纳米制剂及其制备方法
US8815310B2 (en) 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
CN102512404B (zh) 2011-11-18 2014-05-07 上海交通大学 一种姜黄素类化合物肺靶向制剂及其制备方法与应用
EP2799081A4 (en) 2011-12-27 2015-06-24 Tokiwa Phytochemical Co Ltd SIRTUIN ACTIVATOR
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
US8496979B1 (en) 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
WO2013130446A1 (en) 2012-02-29 2013-09-06 Avon Products, Inc. Use of cpt-1 modulators and compositions thereof
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
US9731015B2 (en) 2012-08-04 2017-08-15 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
US9211298B2 (en) 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
DE202012012130U1 (de) * 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
WO2014138426A2 (en) 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN103285401A (zh) * 2013-05-27 2013-09-11 沈阳药科大学 一种能提高难溶性药物溶解性和生物利用度的组合物
US9458086B1 (en) * 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
WO2015072602A1 (ko) 2013-11-15 2015-05-21 (주)다미화학 난용성 물질의 수용액 가용화 조성물 및 이를 이용한 난용성 물질의 수용액 가용방법
WO2015081319A2 (en) * 2013-11-27 2015-06-04 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
TW201540294A (zh) * 2014-04-25 2015-11-01 Caliway Biomedical Co Ltd 用於抑制脂肪細胞、降低體脂肪、減少體重或促進脂肪代謝之植物萃取組成物及其醫藥組合物與用途
CN103989659B (zh) * 2014-05-26 2016-09-07 重庆医科大学 姜黄素纳米结构脂质载体及其制备方法
CN106604724B (zh) * 2014-08-28 2020-05-26 康霈生技股份有限公司 用于减少局部脂肪与减少体重的组合物及其医药品与应用
MX2017002584A (es) 2014-08-28 2017-05-25 Caliway Biopharmaceuticals Co Ltd Composicion y producto medicinal para reducir peso corporal y grasa corporal, y uso del producto.
US10226503B2 (en) 2014-08-28 2019-03-12 Caliway Biopharmaceuticals Co., Ltd. Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
AU2016314546C1 (en) 2015-08-28 2021-07-22 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
CA3033041A1 (en) 2016-08-26 2018-03-01 Caliway Biopharmaceuticals Co., Ltd. A subcutaneous injection formulation for reducing body weight and uses thereof

Also Published As

Publication number Publication date
CA2995158C (en) 2021-05-11
CA2995155C (en) 2021-05-11
SG11201801111RA (en) 2018-03-28
WO2017037594A2 (zh) 2017-03-09
WO2017037593A3 (zh) 2018-08-23
MX2021010359A (es) 2021-10-01
MX2018002462A (es) 2018-06-19
JP7095903B2 (ja) 2022-07-05
TWI630922B (zh) 2018-08-01
CN108697668B (zh) 2022-11-04
MX2018002461A (es) 2018-06-07
RU2753507C2 (ru) 2021-08-17
AU2016314546C1 (en) 2021-07-22
AU2019246808A1 (en) 2019-10-31
AU2016314546A1 (en) 2018-03-01
AU2021202349B2 (en) 2022-12-08
AU2021202349A1 (en) 2021-05-13
CA2995155A1 (en) 2017-03-09
CA2995158A1 (en) 2017-03-09
EP3381451A2 (en) 2018-10-03
US20180250243A1 (en) 2018-09-06
TW201806584A (zh) 2018-03-01
TWI667044B (zh) 2019-08-01
JP2018533545A (ja) 2018-11-15
WO2017037593A2 (zh) 2017-03-09
KR102107917B1 (ko) 2020-05-08
KR102240221B1 (ko) 2021-04-14
AU2016314545C1 (en) 2021-09-23
BR112018003892A2 (pt) 2018-09-25
TW201707686A (zh) 2017-03-01
TW201707685A (zh) 2017-03-01
AU2016314545A1 (en) 2017-11-16
IL257784A (en) 2018-06-28
RU2019108198A (ru) 2020-09-21
TWI604859B (zh) 2017-11-11
JP7054540B2 (ja) 2022-04-14
US20220362173A1 (en) 2022-11-17
CN115778928A (zh) 2023-03-14
CN108697668A (zh) 2018-10-23
AU2016314546B2 (en) 2019-09-12
JP2020143091A (ja) 2020-09-10
KR20200049882A (ko) 2020-05-08
CO2018003424A2 (es) 2018-07-10
WO2017037594A3 (zh) 2018-08-23
IL257784B2 (en) 2023-11-01
KR20200032768A (ko) 2020-03-26
US11433034B2 (en) 2022-09-06
EP3381451A4 (en) 2019-10-09
JP2020128404A (ja) 2020-08-27
EP3381473A2 (en) 2018-10-03
JP2018531220A (ja) 2018-10-25
CN109069655A (zh) 2018-12-21
AU2019246808B2 (en) 2021-01-28
AU2019280037A1 (en) 2020-01-16
IL257784B1 (en) 2023-07-01
JP7063804B2 (ja) 2022-05-09
KR20180037058A (ko) 2018-04-10
RU2019108198A3 (pt) 2020-09-21
KR102356390B1 (ko) 2022-02-08
JP2019528297A (ja) 2019-10-10
KR20180039167A (ko) 2018-04-17
US20180243211A1 (en) 2018-08-30
EP3381473A4 (en) 2019-10-09
US10610496B2 (en) 2020-04-07
JP7063803B2 (ja) 2022-05-09
US20200163906A1 (en) 2020-05-28
AU2016314545B2 (en) 2019-07-11
AU2019280037B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MX2016014281A (es) Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
AR103246A1 (es) Derivados de fgf21 y sus usos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
BR112017009510A2 (pt) composições compreendendo ciclosporina
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem
BR112017019364A2 (pt) dispersões sólidas
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements